Degradation of the extracellular matrix is part of the pathology of ulcerative colitis by Kirov, Stefan et al.
 
  
 
Aalborg Universitet
Degradation of the extracellular matrix is part of the pathology of ulcerative colitis
Kirov, Stefan; Sasson, Ariella; Zhang, Clarence; Chasalow, Scott; Dongre, Ashok; Steen,
Hanno; Stensballe, Allan; Andersen, Vibeke; Birkelund, Svend; Bennike, Tue Bjerg
Published in:
Molecular Omics
DOI (link to publication from Publisher):
10.1039/c8mo00239h
Creative Commons License
CC BY-NC 3.0
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Kirov, S., Sasson, A., Zhang, C., Chasalow, S., Dongre, A., Steen, H., Stensballe, A., Andersen, V., Birkelund,
S., & Bennike, T. B. (2019). Degradation of the extracellular matrix is part of the pathology of ulcerative colitis.
Molecular Omics, 15(1), 67-76. https://doi.org/10.1039/c8mo00239h
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 24, 2020
This journal is©The Royal Society of Chemistry 2019 Mol. Omics, 2019, 15, 67--76 | 67
Cite this:Mol. Omics, 2019,
15, 67
Degradation of the extracellular matrix is part
of the pathology of ulcerative colitis†
Stefan Kirov, *a Ariella Sasson,a Clarence Zhang,a Scott Chasalow, a
Ashok Dongre, b Hanno Steen,cde Allan Stensballe,f Vibeke Andersen, gh
Svend Birkelundf and Tue Bjerg Bennike *cdef
The scientific value of re-analyzing existing datasets is often proportional to the complexity of the
data. Proteomics data are inherently complex and can be analyzed at many levels, including proteins,
peptides, and post-translational modifications to verify and/or develop new hypotheses. In this paper,
we present our re-analysis of a previously published study comparing colon biopsy samples from
ulcerative colitis (UC) patients to non-affected controls. We used a different statistical approach,
employing a linear mixed-effects regression model and analyzed the data both on the protein and
peptide level. In addition to confirming and reinforcing the original finding of upregulation of neutrophil
extracellular traps (NETs), we report novel findings, including that Extracellular Matrix (ECM) degradation
and neutrophil maturation are involved in the pathology of UC. The pharmaceutically most relevant
differential protein expressions were confirmed using immunohistochemistry as an orthogonal method.
As part of this study, we also compared proteomics data to previously published mRNA expression data.
These comparisons indicated compensatory regulation at transcription levels of the ECM proteins we
identified and open possible new avenues for drug discovery.
Introduction
Ulcerative colitis (UC) is a chronic relapsing inflammatory
disorder of the gastrointestinal tract.1–3 The prevalence of UC
is increasing worldwide. In Europe, for example, the incidence
has reached almost 24 cases per 100 000 person-years.4,5 The
disease manifests itself at all ages and it severely affects the
quality of life of the patients and their families. In addition, UC
has a large impact on society, due to interrupted education,
sick leave, and the significant strain it places on the healthcare
system.
The underlying cause of UC is not completely understood,
but both genetics and the environment have been found to be
factors in the disease etiology. More than 230 genetic loci have
been identified as being associated with the inflammatory
bowel diseases (IBD) which, in addition to UC, include Crohn’s
disease (CD).6 Identified genes have been found to be involved in the
epithelial barrier function and both the innate and adaptive immune
response.7 Additionally, a westernized lifestyle and environmental
impact is associated with increased risk of IBD, which may be linked
to changes in the gut microbiome.8 Accordingly, the prevalence in
the West is increasing.9 Cigarette smoking also affects the risk of IBD
and gene-smoking interactions have been identified.10
An early diagnosis and individualized management of the
disease are critical in avoiding irreversible damage to the intestinal
tract. However, finding good treatments remains a challenge due
to the heterogeneous nature of the disease.11–16 Hence, despite the
introduction of biological treatments for UC, colectomy still is
required in 25–30% of the patients at some point during their
lifetime due to the development of colitis refractory to other
treatments.17,18 The intestinal mucosa is critical to inflammatory
processes and regulates immune responses at the interface
between the host and the environment.19–22 It has been previously
hypothesized that initial damage to the intestinal mucosal barrier
results in a misdirected immune response which ultimately leads to
the manifestation of IBD.7 An in-depth characterization of the
intestinal mucosa via molecular profiling technologies would
therefore help to understand the molecular pathophysiology.23
Using a comparative analysis of the proteome in IBD and healthy
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colon mucosa, dysregulated molecular analytes and pathways,
infiltrating myeloid or lymphocytic markers, chemokines, and
inflammatory molecules could be identified. Dysregulated molecular
analytes and pathways could be biomarker candidates (prognostic
or predictive), diagnostics or even potential targets for drug
development.
To investigate this hypothesis, in a previous study the
proteomes of intestinal biopsies from UC patients in remission
and gastrointestinally healthy controls was mapped.23 In this
study a biobank with colon biopsies from ten UC-patients and
ten gastrointestinally healthy controls was established. The UC
patients were in remission and the biopsies were taken with
sigmoidoscopy from macroscopically healthy-looking (non-inflamed)
tissue. The samples were analyzed by high-throughput bottom-up
proteomics using a label-free quantitation strategy. This study lead to
the identification and quantification of 5711 different proteins and
found an increased abundance of neutrophils and neutrophil
extracellular traps (NETs) in the biopsy samples from UC
patients.23
Proteomics data are inherently complex and can be analyzed
at many levels, and statistical analysis of proteomics datasets
can be confounded by a number of factors. We present here our
re-examination of our proteomics dataset comparing UC samples
to gastrointestinally healthy controls, using a different statistical
approach compared to the original study. Employing a linear
mixed-effects regression model, rather than t-tests, and analyzing
the data on the protein and peptide level, we obtained a higher
statistical sensitivity. In this study we confirmed the findings
of the initial publication. In addition, the expanded findings
allowed us to hypothesize that the degradation of the colon
mucosa extracellular matrix (ECM) may play a critical role in
the pathology of UC, in addition to neutrophil extracellular
traps (NETs).
Materials and methods
Proteomics data acquisition
For the original study,23 colon biopsies were taken from ten UC
patients and 10 gastrointestinally healthy controls with sigmoido-
scopy from macroscopically healthy-looking (non-inflamed) tissue at
the Regional Hospital Silkeborg in Denmark. The samples were
immediately snap-frozen in liquid nitrogen and stored at 80 1C
until time of processing within one year. The samples were prepared
for bottom-up proteomics analysis using a label-free quantitation
strategy. Briefly explained, the biopsies were homogenized using
steel beads and digested using a filter-aided sample preparation
protocol with the protease trypsin. The samples were analyzed by
high-throughput bottom-up proteomics on a UltiMate 3000 UPLC
system (Thermo Scientific, Waltham, MA) coupled online to a Q
Exactive Plus mass spectrometer (Thermo Scientific), operated
in a data-dependent TOP12 mode. The proteomics raw data
were deposited by Bennike et al.24 to the ProteomeXchange
Consortium via the PRIDE ProteomXchange repository with
the dataset identifier PXD001608. The study material was com-
posed of colon mucosa biopsies from ten UC patients and ten
gastrointestinally healthy controls. These data were retrieved
from the PRIDE EBI archive using wget.
Proteomics search
The sequence database for proteomics searches was assembled
from a combination of Ensembl, Refseq and Uniprot databases.
In addition, Refseq annotation was used to add fragments unique to
mature proteins. We used MaxQuant 1.5.3.825 to accomplish all
protein identification searches. MaxQuant configurations associated
with each search are provided in the (available in the downloadable
Supplementary Materials file, ESI†) section.
The proteinGroups.txt file produced by the MaxQuant search
was used for quality control (QC) of the dataset. The QC report
was generated using Rstudio26 running R version 3.3.1.27 From
these initial plots of raw Intensity and LFQ (DP = 2), none of the
samples was deemed to be of significant concern and thus all
samples were included in the subsequent analysis.
The results presented throughout this paper are based on
our analysis of protein groups as defined by MaxQuant; for
simplicity we are going to refer to those as proteins.
Statistical models
Filtering. We removed all proteins where too many data
points were missing, using both sample-frequency (66% per
group) and donor-frequency (70%) thresholds. Since we had
30 samples (3 replicates in 10 donors) per group, a protein that
had no readout in 10 or more samples in each group would be
considered non-quantifiable and would be eliminated from
further analysis. Similarly, proteins considered for further
analysis had to be present in at least 7 donors in either group.
Imputation. We imputed missing values for quantifiable
proteins using the minimum LFQ value in the sample where
the missing data point was present. This represents a conservative
approach in most cases, as such imputation of values missing at
random would likely increase the variability within a group and
therefore increase the p-value.
Differential expression analysis. We fit a linear mixed-effects
regression model of Intensity, with a fixed effect of DiseaseState
(UC versus controls) and a random Donor effect, using function
lme from the R package ‘‘nlme’’.28 We controlled for false
discovery by applying the Benjamini–Hochberg correction
method. Proteins were considered to be significantly differentially
regulated at 5% FDR and 0.5 log2-fold-change. Peptides were
considered to be significantly differentially regulated at 5% FDR
and 1 log2-fold-change.
Differential modification analysis. To test for the presence
of global shifts in modifications (hydroxyproline oxidation,
ubiquitination), we averaged the raw intensity from all peptides
carrying the specific modification for each donor within the
control and UC group. We then applied a two tailed t-test to
those averaged values for each group.
Microarray data and correlation analysis. Microarray data
were retrieved from GEO. Three datasets were reanalyzed:
GSE3871329 (referred to as Plannell), GSE1061630 (referred to
as Kugathasan), and GSE945231 (referred to as Olsen). Each
dataset was RMA normalized. Only probesets with an expression
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level more than log2 RMA of 3.5 in at least 10 samples were
considered. Fold change values were determined for the control
subjects vs. the UC patients (Table 1).
Fold change values for probesets were collapsed to a gene
level by taking the median. Pearson pairwise correlations were
then calculated for all microarray sets and the proteomics data.
The list of proteins with significant disagreement between
RNA expression and protein levels was compiled by thresholding
for mass spec fold change and microarray median fold change
and sorting by the mass spec fold change. The directionality and
downregulation of proteins was stored as a Boolean vector.
Pathway analysis. Differentially regulated peptides were converted
to protein identifiers using the peptides.txt file. Protein identifiers
were converted to EntrezGene identifiers using a combination of
conversion techniques according to the source of the originating
protein ID (Refseq, Ensembl and Uniprot).
We split the lists into up- and down-regulated sublists and
examined each list separately with WebGestalt and GSEA.
Webgestalt32 was used to explore GO enrichment and GSEA was
used to explore other ontologies and gene lists, such as MSIGDB,
Reactome (www.reactome.org) and Pubmed (www.ncbi.nlm.nih.
gov/pubmed/).
Both tools allowed lists of genes to be uploaded and to serve
as background models and we used all identified proteins to
define the background reference.
Reproducibility
Most results from this analysis (hits lists, graphs, etc.) can be
reproduced on a Linux system with R 3.3.1, perl and several R
packages (listed available in the downloadable Supplementary
Materials file, ESI†). Once all input datasets are downloaded
along with the scripts, executing reproduce.sh would generate
identical results to those we communicate in this paper. All
datasets and scripts necessary to reproduce these findings are
downloadable from http://pubd.web.bms.com/.
Immunohistochemistry
Formalin-fixated colon biopsies24 were paraffin embedded, cut
in 10 mm sections, mounted on Superfrost Plus slides (Thermo
Scientific) and deparaffinized. Sections were blocked with 0.1%
bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for
1 hour. Thereafter, the sections were incubated for one hour with
the primary antibody in 0.1% BSA in PBS using either 2 mg ml1
rabbit anti-Protein S100-A9 (Abcam, Cambridge, UK), 2 mg ml1
mouse IgG1 anti-Protein S100-A12 (Abcam), 2 mg ml1 rabbit anti-
myeloperoxidase (ab9535, Abcam), 2 mg ml1 isotype control mouse
monoclonal IgG1, or 2 mg ml1 rabbit IgG. Sections were washed
3 times with PBS. The samples were then incubated for 1 hour in
PBS with the secondary antibody using either TRITC conjugated
goat anti-rabbit IgG or TRITC conjugated goat anti-mouse IgG
(Jackson ImmunoResearch, Bar Harbor, ME). The samples were
then diluted 1 : 200 in PBS with 0.1% BSA. To stain for DNA, the
sections were washed in PBS and incubated for 30 minutes with
1 mM ToPro-3 (Thermo Scientific) in PBS. The slides were analyzed
with an SP5-confocal microscope (Leica, Wetzlar, Germany) using
an HC PL APO 63/1.40 Oil objective (Leica) and the data was
analyzed in ImageJ.33
To provide a semi-quantitative addition to the proteomics
data, the stain intensity surrounding the 10 cells with the highest
staining intensity was averaged for each confocal microscopy
image using ImageJ 1.48v. The intensities between the samples
was compared by two sample t-tests in R.
Results
Quality control
We have established an R-based pipeline to comprehensively
evaluate the quality of proteomics data (manuscript in preparation).
A full quality report is available in the (available in the downloadable
Supplementary Materials file, ESI†).
We used the quantro R package34 to evaluate global effects
and observed no statistically significant change in protein intensities
between the UC and control groups ( p = 0.11, 10 000 simulations).
We therefore applied median centering as a global normalization
method.
Protein level analysis
This study aimed to identify proteins differing in abundance on
average between the UC and control groups. For this purpose
we performed linear regression analysis based on the protein
groups generated by MaxQuant.
We identified a similar number of protein groups – 6399 –
compared to the original study where 6268 were identified.
After rigorous filtering, 5093 proteins were considered to be
quantifiable, versus 5711 in the original publication. However,
our statistical model allowed us to identify substantially more
differentially regulated proteins: 251 versus 49 in the previous
study. This difference reflects two methodological differences:
different filtering and imputation strategies, and the linear
mixed effects model we used that allowed us to take advantage
of the technical replicates, which had been averaged in the
original study. Including a random donor effect to allow for
intra-donor correlations between technical replicates allowed
the assessment of technical variability and increased statistical
power of hypothesis tests.
As with the original study we were able to establish statistically
significant overlap with NETs (hypergeometric test, p o 0.001), most
significantly with NET granules.35 We were able to confirm the
presence of a neutrophil immune cell signature also based on
MSIGDB.36
Of the differentially regulated proteins, 90 had increased
and 161 had decreased abundance in the UC samples. However,
9 of the top 10 proteins with the largest absolute expression
difference (Table 2) were upregulated, signifying the larger
Table 1 Number of participants in the three microarray studies
Study Controls Ulcerative colitis
Olsen31 5 21
Planell29 13 30
Kugathasan30 16 10
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effects observed in diseased tissue. The only downregulated
protein in the top 10 is elastin, an indication of changes in the
extracellular matrix. This observation is in line with previous
research implicating bacterial or host proteases in the degradation
of the ECM in IBD.37,38
We compared our results to previous research of differential
gene expression in transcriptomics datasets, comparing colon
biopsies from UC-patients to controls. For that purpose we
selected 3 publicly available transcriptional profiling datasets.29–31
We extracted the lists of differentially regulated genes from the
microarray data and then calculated the log2 ratio for all sets,
including the present proteome dataset. All further comparisons
were based on this metric. Merging between datasets was done
using a translation table available in the (available in the down-
loadable Supplementary Materials file, ESI†). We were able to
match 219 of the 251 hits in all datasets. Overall the correlation
between the transcriptional profiling studies is high. In contrast,
the correlation to our proteomics dataset was moderate with
R r 0.38 (Fig. 1 and Fig. S1, ESI†). Unlike mRNA-protein level
correlation, for which we anticipated low correlation based on
established research,39 we expected differentially expressed
proteins to exhibit greater correlation when fold changes were
used for comparison.40
Surprisingly, genes that were highly expressed in neutro-
phils and are considered granulocyte markers showed different
direction changes in the proteomics data and even between
different transcriptional studies. Myeloperoxidase (MPO), for
example, is well studied and known to be highly induced in
active UC.41 The reverse observation may be the result of a
suboptimal design of microarray probesets. The lack of high
correlation may be due to post-translational events, differences
in general technologies, or sample selection. Another possible
explanation would be that transcription is halted when secretory
granules are full, resulting in high protein levels, but low
transcript abundance.
There also were significant differences between the transcrip-
tional and protein fold changes when examining the downregulated
proteins (Supplementary File 1, ESI†). A substantial number49 of the
149 downregulated proteins were either upregulated (log2 ratio 4
0.5, n = 16) or unchanged with log2 ratio between 0 and 0.5 (n = 33).
Most of these proteins (Table 3) are part of the ECM.
Table 2 The top 10 differentially regulated proteins when comparing the UC and control groups. The list is filtered by FDR adjusted p-value (p o 0.05)
and sorted by effect size (log2 ratio). Complete table of the differentially regulated proteins is available as Supplementary File 1 and the non-filtered data is
available in Supplementary File 2 (ESI)
Protein acc. p-value FDR Entrez gene log2 ratio Description Gene NETs protein
NP_002334 8.57  1012 4.37  108 4057 7.45 Lactotransferrin LTF Yes
XP_011523124 2.02  1013 1.03  109 4353 6.76 Myeloperoxidase MPO Yes
NP_004985 1.87  1012 9.52  109 4318 6.06 Matrix metallopeptidase 9 MMP9 Yes
XP_011545190 2.93  107 1.49  103 1991 5.02 Elastase, neutrophil expressed ELA2 Yes
NP_001691 1.28  108 6.50  105 566 4.92 Azurocidin 1 AZU1 Yes
XP_011514177 5.16  1013 2.63  109 2006 4.88 Elastin ELN No
NP_002956 2.13  109 1.09  105 6280 4.67 S100 calcium binding protein A9 S100A9 Yes
NP_000623 2.02  1010 1.03  106 3684 4.53 Integrin subunit alpha M ITGAM No
NP_002768 6.37  107 3.24  103 5657 4.49 Proteinase 3 PRTN3 Yes
XP_005260579 8.75  1010 4.46  106 671 4.45 Bactericidal/permeability-increasing protein BPI No
Fig. 1 The Pearson correlation matrix based log2 ratios in microarray and
protein expression data.
Table 3 Top 10 of the proteins where significant disagreement between
protein log2 ratios and transcriptional profiling ratios were observed,
ranked by mass spec log2 fold change
Protein MassSpec Olsen Planell Kugathasan
Mean
of all
arrays Symbol
NP_005469 3.25 0.55 0.19 1.06 0.60 INSL5
XP_005252935 2.42 0.26 0.02 1.53 0.60 OLFML1
XP_011508876 2.37 1.57 1.94 2.41 1.97 COL6A3
NP_001034438 2.15 0.24 0.39 1.92 0.69 EFEMP1
NP_060150 1.71 0.26 0.27 1.29 0.60 ASPN
NP_001129408 1.41 0.92 0.64 1.08 0.88 POSTN
XP_011519350 1.34 1.41 1.67 1.86 1.65 COL4A1
NP_002014 1.13 0.36 0.44 1.48 0.76 FMOD
NP_001275908 1.09 1.70 0.48 1.69 1.29 LIPA
NP_000129 1.02 0.95 0.60 2.01 1.19 FBN1
NP_000080 1.00 1.44 1.43 1.86 1.58 COL1A2
NP_001837 0.95 0.94 0.64 1.26 0.94 COL4A2
NP_004376 0.84 1.20 0.77 2.18 1.38 VCAN
XP_006719333 0.66 1.14 0.71 2.23 1.36 DCN
NP_001702 0.64 0.75 0.72 0.52 0.66 BGN
XP_011527754 0.61 0.38 0.77 0.58 0.58 COL6A2
In bold-bona fide components of the extracellular matrix (ECM).
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Anecdotal reports of similar phenomena have been recorded
in the past. For example, collagen protein is known to be lost
due to degradation in models of IBD, and PGP fragments are
subsequently increased.42 This degradation of collagen could
trigger compensation at a transcriptional regulation level and
would explain the upregulation seen in the microarray studies29–31
we examined. In a recently published RNA-Seq dataset,43 3 of the
genes we found to be upregulated as transcripts, but at decreased
protein levels were confirmed to be increased as transcripts as well
(Table S2, ESI†).
Chromogranin A
In addition to the protein level analysis, we also looked at
differential expression at the peptide level (available in the
downloadable Supplementary Materials file, ESI†). This analysis
may occasionally highlight differences in protein processing
and secretion. We decided to look specifically at chromogranin A,
as the log2 ratio for the identified peptides originating from this
protein showed substantial dispersion. The variability of most
peptides is higher in the UC group because of more imputed
values.
Chromogranin A (CHGA) is a protein that is post-translationally
processed to multiple hormones and functional peptides.44,45
While chromogranin A was one of the differentially regulated
proteins, it was not a top hit. CHGA ranked in the top 28.17% of
all hits (71/252) in terms of fold change (log2 FC = 1.77, FDR =
0.0015). At the peptide level, differential regulation was more
pronounced with fold changes ranging from 3.7 to 5.7, and
the top peptide ranked at the top 6.54% of all hits (42/642). The
reason for this discrepancy is that some of the peptides were
significantly downregulated in UC (Fig. 2), while others were only
marginally higher in controls. For all peptides, the characteristics
and fold change differences between tissues from healthy controls
and UC patients are given in the (Supplementary File 3, ESI†).
Identification of CHGA sub-regions as some of the most signifi-
cant peptide hits (available in the downloadable Supplementary
Materials file, ESI†) allowed us to describe EA-92, chomofungin,
serpinin, and pancreastatin as potential biomarkers and perhaps
targets in the context of UC. In addition, we can now speculate on
the involvement of EA-92 in inflammation.
Significant changes occurred in four peptide regions. These
regions overlap with the biologically active peptides serpinin,
vasostatin and chromofungin that are known to have anti-
microbial activity.46,47
As we did not intend to explore bioactive peptide expression,
it is hard to define exactly which functional regions are differentially
regulated. We can speculate, for example, that the CHGA down-
regulated peptide probably originates from chromofungin,
since changes in other vasostatin I and vasostatin II peptides
were not statistically significant. We also observed significant
changes in EA-92, but some peptides originating from the same
region were not consistent with this change. It is possible that
EA-92 is further processed into a shorter mature product.
Decreased hydroxyproline in ulcerative colitis
Collagen is a central ECM protein and degradation of it has
been associated with IBD.42 Hydroxyproline modifications correlate
well with collagen content, collagen protein abundances, and the
degree of fibrosis48 which can be found in 430% of CD patients
and about 5% of UC patients.49,50 We therefore decided to
include a quantitative analysis of the hydroxyproline PTM
content. In addition, ubiquitination has been implicated in
IBD and was for that reason also included in the analysis.51
We did not observe differential regulation of any of the individual
amino acid sites, either for hydroxyproline or ubiquitinated PTMs.
Additionally, we did not observe a statistically significant difference
between total or peptide specific ubiquitination ( p = 0.146). However,
the overall abundance of peptides with a hydroxyproline modifica-
tion was significantly lower in the UC colon tissue compared to
control (Fig. 3), which is consistent with the reduced abundance
of collagen proteins determined by proteomics and previously
published research of collagen degradation.52
Fig. 2 Mean normalized intensity of chromogranin A peptides in ulcerative
colitis (UC) and controls (ctrl) according to the position of the individual
peptides in the full protein sequence.
Fig. 3 Overall change in hydroxyproline modified peptide abundance in
ulcerative colitis (UC) compared to controls (Ctrl), demonstrates a reduced
abundance in UC (p-value = 1.12  107, Welch two sample t-test).
p-Value = 1.12  107, Welch two sample t-test.
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Pathway analysis
We explored the presence of over-represented categories from
several different ontologies using lists of upregulated and
downregulated features at the peptide and protein levels. When
using the GO Biological process ontology and comparing to our
protein-level list (available in the downloadable Supplementary
Materials file, ESI†), most categories were related to the immune
system. The most significant category we observed was ‘‘Response
to bacteria’’. We also observed the enrichment of leukocyte
migration, which is a hallmark feature of IBD.53 At the same time,
downregulated proteins significantly overlapped with extracellular
structure organization as well as mitochondrial respiratory
complex assembly and glycosylation (available in the download-
able Supplementary Materials file, ESI†). While mitochondrial
changes have been previously implicated in the pathogenesis of
IBD,54 the association of ECM categories with downregulated
proteins was largely unexpected. This observation was consistent
with the decreased hydroxyproline levels and the data we obtained
by comparing transcriptional profiling data with the list of
differentially regulated proteins.
Next, we explored additional ontologies and gene lists,
including MSigDB and Pubmed (available in the downloadable
Supplementary Materials file, ESI†). Most lists we identified as
significantly overlapping with our list of upregulated proteins
were related to immune function, and further reinforce the
neutrophil association. One category also of interest is Reactome’s
‘‘Degradation of extracellular matrix’’, which is consistent with
decreased hydroxyproline levels and collagen protein, supporting
our hypothesis. In addition, it appears that lists associated with
cell line proliferation (stem cells, cancer) overlap significantly with
our downregulated list of proteins.
In the GO Component ontology, only one category was enriched
in the list of upregulated peptides: ‘‘Blood microparticles’’ (Fig. S6,
ESI†). Blood microparticles (MPs) have been associated previously
with inflammation and infection, including Crohn’s disease.55
Secreted MPs or secreted Microvesicles (sEV) are a diverse range
of lipid vesicles containing a cargo of protein and RNA/DNA
originating from a range of cell types including neutrofils.56
IHC confirmation
Colon biopsy sections from 4 UC patients and 2 healthy controls
were stained for the proteins S100-A9 and S100-A12, or for
myeloperoxidase, all of which are present in granulocytes. In
Fig. 4, results from one patient with ulcerative colitis and one
healthy control are shown. No reaction with antibodies to S100-
A9 and S100-A12 was observed in sections of the healthy control
(Fig. 4, A and D) or in immunoglobulin controls (Fig. 4F and I),
showing that granulocytes are not present in healthy intestinal
mucosa (mucous epithelium and lamina propria). A strong
staining was observed for S100-A9 in the UC patients, and, in
addition, more cells were observed in lamina propria than in
controls (Fig. 4B). By enlarging the image, it can be seen that
cells stained for S100-A 9 are polymorphonuclear (Segmented
nuclei), in agreement with granulocytes, and S100-A9 is located
in the cytoplasm of the cells (Fig. 4C). It can also be seen that the
S100-A9 contained in polymorphonuclear cells are located between
the mucosal epithelial cells (Fig. 4B and C). S100-A12 are also
present in the cytoplasm of polymorphonuclear cells in the UC
patient (Fig. 4). Myeloperoxidase shows a similar staining pattern
as S100-A9 and S100-A12, in agreement with its localization in
granulocytes. An analysis of the staining intensity confirmed the
statistically significant (t-test p-value o0.001) increase of S100-A9,
S100-A12, and MPO in the UC colonic biopsies compared to
controls (Fig. S4, ESI†). The main function of MPO is remodeling
of the ECM during degradation, hence the increased abundance
of MPO as determined by proteomics and validated by immuno-
fluorescence underlines the degradation of the colonic ECM
during UC.
Discussion
One of the most unexpected results we report here, supported
by several separate findings, is the presence of significantly
lower levels of multiple ECM proteins in intestinal biopsies
from UC patients. Such downregulation can occur as a result of
either modulation of transcriptional and translational activity
or degradation and displacement (with the second explanation
being more likely based on microscopy findings). The notion
that degradation drives the changes we observe is further
supported by the increased detection of ECM matrix fragments,
Fig. 4 Confocal microscopy of colon biopsies from a healthy control and
an ulcerative colitis patient. (A) Healthy control, (B and C) ulcerative colitis
patient stained with anti-protein S100-A9. Healthy control (D and E)
Ulcerative colitis patient stained with anti-protein S100-A12. (F) Isotype
control with mouse IgG1 monoclonal antibody. (G) Healthy control stained
with anti-myeloperoxidase and (H) ulcerative colitis patient. (I) IgG control
of ulcerative colitis patient section stained with normal rabbit IgG. Nuclei
are stained red with To-Pro3. The bar indicates 25 mm in the picture (A), (B),
(D–I) and 10 mm in (C).
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reported in the serum of UC patients vs. controls or CD
patients.57,58 Of note, the current study is not powered to make
definitive conclusion regarding the general population, and the
hypotheses we raise require extensive confirmatory studies.
Fibrosis is a well described complication of IBD,59 especially
in CD.49,50 Therefore, we expected to observe upregulation of
collagen proteins and hydroxyproline-containing peptides.
Indeed, increases in collagen transcripts were found with all
3 previously published transcriptomics datasets.29,31,60 However,
among current proteomics datasets several collagen proteins
were found to have lower abundances in the UC group. The
discovery of decreased collagen protein abundance in UC was
supported by a lower abundance of hydroxyproline-containing
peptides, and was in agreement with previous reports of UC colon
mucosa.61 The UC patients in our proteomics study were all
medicated and no visible inflammation could be observed on
the surface of the colon from which the biopsies were taken.
Additionally, the histology analysis of the colon biopsies found
that the crypt architecture was preserved and without distinct
fibrosis, which is in agreement with the proteomics findings.
However, an increased presence of neutrophils, NETs, and pro-
inflammatory proteins could be detected with proteomics, and
validated by immunofluorescence. We speculate that these
seemingly contradictory findings between the collagen protein
abundances and the transcript levels are two sides of the same
complex process. It is possible that an active process caused by or
causing the degradation of the ECM would lead to a compensatory
yet insufficient transcriptional response. The comparisons between
microarray, RNA-seq, and proteomics data underline the notion
that mRNA abundances cannot be directly translated to protein
abundances, but rather are a proxy for the protein synthesis-rates.
Taken together, the findings indicate the presence of a low-grade
inflammation in the tissue, which could trigger the degradation
of collagen. It would be interesting to learn the turnover of ECM
proteins in the active sites of the disease. Increased rates would
support our hypothesis, and increased ECM protein turnover has
already been observed in the bleomycin model of pulmonary
fibrosis.62
Consistent with ECM degradation, we detected increased
abundances of ECM degrading enzymes, including myeloblastin,
neutrophil collagenase, MMP9, and MMP10. However, our data
somewhat surprisingly cannot confirm that MMP9 and MMP10
upregulation is the cause for the ECM protein degradation as we
could not detect increased abundance of the activated MMP
fragments, suggesting a lack of MMP activation. This observation
requires further validation as we are basing this hypothesis
on known MMP substrates which may not represent the full
diversity, thus potentially skewing the results. In addition, it is
possible the current proteomics workflow may not be able to
assess the presence of MMP fragments fully. However, the increase
in MMP proteins is consistent with the reduced abundance of
collagen proteins and hydroxyproline, and by extension the
reduction in ECM protein content, thus adding credibility to
the potential of ECM degradation as a major event in IBD
pathology. We can further speculate that ECM degradation
is an initial trigger for both neutrophil infiltration and ECM
transcriptional activation which may overcompensate and even-
tually result in fibrosis. Purely speculatively, ECM degradation
could be triggered partially by leaky epithelial tight junctions
in intestinal inflammation. Tight junctions are multi-protein
complexes that form a seal between adjacent epithelial cells,
and thus act as barriers that normally regulate the transport of
macromolecules. UC genetic studies have identified susceptibility
loci related to defects of the epithelial barrier,63,64 and IBD
patients often demonstrate a loss of tight junction functions.
While not sufficient to cause IBD, the loss of the tight junction
function causes an immune activation.65 Accordingly, epithelial
leaks can be detected early in UC,66 and it has been suggested
that these barrier defects allow bacterial antigens to enter the
mucosa from the lumen, causing inflammation of the mucosa
which could lead to ECM degradation.67 Degradation of ECM
proteins could potentially have an impact on IBD pathology. It
has been reported that proteolytic fragments (PGP) of ECM
proteins can serve as neutrophil chemoattractants through
CXCR1.68 PGP has also been identified as a potential biomarker
in COPD, another disease where inflammation and neutrophil
infiltration play a major role.69 Taken together, emerging evidence
of ECM protein degradation and peptidase involvement in the
pathology of UC may open new opportunities for biomarker
discovery and novel therapeutic options.
We also observed another interesting example of disconnect
between protein and mRNA regulation of Chromogranin A (CHGA).
CHGA is a great example of a situation where the mRNA and its role
in the generation of multiple hormones was characterized decades
ago,44,70,71 yet we continue to find novel proteoforms originating
from this locus.46 Chromogranin A upregulated peptides also
diverge significantly in terms of differential regulation, potentially
due to the different regulation and/or secretion of the many
proteoforms that are encoded by this locus. While chromogranin
A itself is differentially regulated, specific regions of the protein
exhibited much larger differences between UC patients and the
control population.
An elevated level of NETs is closely associated with general
inflammation by the release of a extracellular lattice, composed
of DNA associated with proteins citrullinated by protein-arginine
deiminase 4 (PAD4) from neutrophils.72 The NETosis or NETlysis
processes are associated with a range of autoimmune diseases
or triggered by inflammatory activation including UC and
reumatroid arthritis.24,73 Berthelot et al. have found that NETosis
increases the possibility of association between autoantigens and
infectious antigens in mucosal biofilms, impairing the clearance
of pathogens and possibly triggering autoimmune reactions
such as autoantibody formation (ANCAs). These autoantibodies
against NET components have been suggested as possible
explanations for the breakdown of tolerance to NET autoantigens,
such as hypercitrullination. Of the NETs granule proteins identi-
fied in this study, LTF, MPO, and PRTN3 have been associated
with autoantibody formation in relation to IBD and ECM-related
processes.74 The release of active PAD2 and PAD4 isoforms into
synovial fluid by neutrophil cell death is a plausible explanation for
the generation of extracellular autoantigens in RA.75 The inhibition
of PADs by either small molecule drugs or biologics has been
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implicated in treatment strategies for autoimmune diseases such as
RA but no evidence for such potential has been provided so far.76
Conclusion
One could argue that proteomics data are more complicated than
other OMICs data. RNASeq- and DNASeq-data have a single output:
variants and/or transcript expression. In contrast, proteomics
data can be analyzed in different contexts-expression levels as well
as post-translational modifications, and variations. In addition,
the field has a much better understanding of splicing isoforms
than of proteoforms. All this presents a significant challenge to the
community. Therefore, in this work, we re-investigated an existing
proteomics dataset, and confirmed and extended the original
findings. Some of the differences in the data analysis method
included variations in the proteomics identification, filtering, and
imputation procedures. However, the largest contributor to the
new observations and results can be ascribed to the different
statistical test that was applied. In the original dataset, statistically
significant proteins were identified mainly using t-tests. In
comparison, in this reanalysis, we used tests based on linear
mixed effects models, which allowed us to include the replicates
in the statistical analysis rather than combining them, thereby
increasing the number of significant proteins identified sub-
stantially. Combining these findings with an existing microarray
and RNAseq-dataset, allowed us to draw novel conclusions,
including ECM degradation in UC. In addition to the increased
understanding of the pathophysiology of UC, our work demon-
strates the significant value in sharing raw data with the
community through resources such as PRIDE to enable such
cross-OMIC analyses.
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